Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer

Table 2 Summary of the ongoing trails

ID	Identifier	Design	Status	Participants	Sample	Stage	Intervention	Outcome measures
NCT04385368 [95]	MERMAID-1	RCT	Recruiting	NSCLC with MRD + after surgery	332	II-III	Drug: adjuvant durvalumab + chemotherapy Other: placebo + adjuvant chemotherapy	DFS; OS
NCT04642469 [96]	MERMAID-2	RCT	Recruiting	NSCLC with MRD + after surgery	284	II-III	Drug: durvalumab Other: placebo	DFS; OS
NCT04367311 [97]	BTCRC-LUN19-396	Non-RCT	Recruiting	NSCLC after surgery	100	I-IIIA	Adjuvant chemotherapy + atezolizumab	Percentage of patients with undetectable ctDNA; DFS
NCT04585477 [98]	LUN0115	Non-RCT	Recruiting	NSCLC after surgery or SBRT	80	I-III	MRD + cohort 1: adjuvant durvalumab MRD − cohort 2: SoC	Decrease in ctDNA level; OS; DFS; irAEs
NCT04585490 [99]	LUN0114	Non-RCT	Recruiting	Unresectable NSCLC	48	III	MRD + cohort 1: chemotherapy + durvalumab MRD − cohort 2: durvalumab	Change in ctDNA Level; PFS; OS; irAEs

RCT randomized controlled trial, NSCLC non-small cell lung cancer, MRD minimal residual disease, SoC standard of care, ctDNA circulating tumor DNA, OS overall survival, DFS disease-free survival, PFS progression-free survival, SBRT stereotactic body radiation therapy, irAEs immune-related adverse events

ISSN: 1741-7015